P-VERIFY: Real-World Comparative Overall Survival and Progression-Free Survival of CDK4/6 Inhibitors Plus an Aromatase Inhibitor in Patients with HR+/HER2− Metastatic Breast Cancer in the USA—A Vodcast
Randomized trial compares overall survival and progression-free survival in HR+/HER2- metastatic breast cancer, indicating no significant differences between treatments.
Key Points
To compare the overall survival and progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer.
Retrospective comparative effectiveness study using Flatiron Health Analytic Database.
Identified 9146 patients initiating first-line treatment with palbociclib, ribociclib, or abemaciclib plus an AI.
Statistical analyses included stabilized inverse probability treatment weighting.
No significant differences in overall survival (OS) and real-world progression-free survival (rwPFS) across treatment groups (hazard ratios 0.95 to 0.98, all P > 0.05).
Results remained consistent across sensitivity and subgroup analyses.
Findings support that there are no significant differences in OS and rwPFS in patients treated in routine clinical practice.